The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 6, 2022. Its latest SEC filing is a 15-12G from Aug 1, 2022.
10-Q for Q1 FY2022, filed May 6, 2022
The sections below describe the company as of the FY2021 annual report.
Sells diagnostic, monitoring and treatment devices, supplies and services for neurological disorders to hospitals, clinics and other healthcare providers.
10-K for FY2021, filed Feb 25, 2022Our neurocritical care solutions include management of traumatic brain injury by continuous monitoring of intracranial pressure (“ICP”) and…View ↗
Our Neuro portfolio is comprised of a comprehensive line of neurodiagnostic, neurocritical care, and neurosurgical products that are used…View ↗
We design, manufacture, and market a full line of instruments and supplies used to help diagnose the presence of seizure disorders and…View ↗
Customers pay for most devices and supplies when products ship. Separately priced service contracts are paid up front, while the company provides coverage over the service period; installation and training fees are also billed up front.
10-K for FY2021, filed Feb 25, 2022For the majority of devices and supplies, we transfer control and recognize revenue when products ship from the warehouse to the customer.…View ↗
We sell separately-priced service contracts that extend maintenance coverages for both medical devices and data management systems beyond…View ↗
Contract assets for the periods presented primarily represent the difference between revenue recognized based on the relative selling price…View ↗
$473.4M
10-K for FY2021, filed Feb 26, 2022
$473.4M ↗
Healthcare providers in North America generally buy through Natus's direct sales team, with some products sold through private-label and distribution arrangements. International customers buy directly in some markets or through distributors that resell to end users or other resellers.
10-K for FY2021, filed Feb 25, 2022We sell our products in North America primarily through a direct sales organization. We believe this direct sales organization allows us to…View ↗
We sell some of our products outside the U.S. through direct sales channels in Australia, Canada, China, Denmark, France, Germany, Italy…View ↗
We sell products to our distributors under substantially the same terms as sales through our direct sales channels. Terms of sales to…View ↗
Yes. It kept 3 cents of every revenue dollar as net income in FY2021 and turned 13 cents into free cash flow.
10-K for FY2021, filed Feb 26, 2022
$23.8MView ↗
10-K for FY2021, filed Feb 26, 2022
$13.2MView ↗
10-K for FY2021, filed Feb 26, 2022
$60.4MView ↗
8-K, filed Jul 21, 2022
ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity valueView ↗
8-K, filed May 5, 2022
On April 18, 2022 the Company announced that it entered into a definitive agreement to be acquired by an affiliate of ArchiMed for…View ↗
8-K, filed Apr 18, 2022
MIDDLETON, WI (April 18, 2022) – Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical…View ↗
Held flat. Revenue was $473.4M in FY2021, about the same as the $501M of FY2017.
Loading...
